Back to School: How biopharma can reboot drug development. Access exclusive analysis here
AMGN reported second quarter EPS of $0.49, beating the Street consensus estimate by $0.03. Second quarter EPS were up 29% compared to $0.38 for the
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury